Product Description
Novartis was developing qbm-076, an oral CXCR2 Antagonist for Chronic Obstructive Pulmonary Disease . (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01972776)
Mechanisms of Action: CXCR2 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Chronic Obstructive Pulmonary Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| 2012-005615-92 | P2 |
Terminated |
Chronic Obstructive Pulmonary Disease |
2015-06-12 |
2022-03-13 |
Treatments |
|
| CQBM076X2203 | P2 |
Terminated |
Chronic Obstructive Pulmonary Disease |
2015-05-01 |
2019-03-20 |
Recent News Events
Date |
Type |
Title |
|---|